|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||0.352 - 0.382|
|52 Week Range||0.047 - 2.460|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Pivot Signs Letter of Intent With Pharmaflorx For Supply Of Cannabis Oils And Isolates Minimum of 1,000 KG/Annually For Use In Pivot's Product Pipeline
VANCOUVER , Aug. 9, 2018 /PRNewswire/ - Pivot Pharmaceuticals Inc . (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT ) ("Pivot" or the "Company") is pleased to announce the signing of a Letter ...
Based in Las Vegas, Nevada, HOPE is a fully licensed extractor, manufacturer and distributor of cannabis products including effect-based vape cartridges, syringes, micro-dosed oral sprays, pre-rolls, infused pre-rolls, infused cold brew coffee and infused lemonade.
Pivot Monetizes "RTIC" Technology And Enters Nevada Cannabis Market With Strategic Partner
VANCOUVER , Aug. 7, 2018 /PRNewswire/ - Pivot Pharmaceuticals Inc . (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT ) ("Pivot" or the "Company") is pleased to announce that it has signed a Definitive ...
Pivot Acquires Rights To Patented Solumer™ Oral Drug Delivery Technology Ideal For Use In Cannabis-Infused Beverage Formulations
Pivot Signs Exclusive Co-Marketing And Distribution Agreement with Swiss-based S.T.U. GmbH, Establishes Large Retail and Online Sales Channels In The European Union
Under the terms of the Agreement, S.T.U. will market and sell Pivot's proprietary cannabinoid-derived products online and in retail outlets in the U.K., Switzerland, Germany, Austria and Italy (where regulations permit). In addition, Pivot will distribute the Hemplix™ product line in Canada, Latin America and the United States, where regulations permit and upon receipt of necessary licenses from regulatory authorities. Hemplix™ CBD oil was developed in Switzerland by Swiss pharmacists, using organically cultivated cannabis plants.
Pivot Pharma To File Investigational New Drug (IND) Application With U.S. FDA For PVT-005
HSDD, the most common type of female sexual dysfunction ("FSD"), affects approximately 12 million women in the U.S. alone. The condition is characterized by low sexual desire and marked distress which are not attributable to existing medical, pharmacologic, psychiatric, or relationship issues.
The Option expires in 6-months during which time Pivot will determine compatibility with Pivot's RTIC powder formulations. Upon successful completion of the evaluation Pivot will have the Option to enter into a Definitive Licensing Agreement with IP Med for the TriVair™ device.
Pivot Naturals will immediately submit an application to obtain a Marijuana Business Permit, as well as a Conditional Use Permit and a Business License. Businesses in Costa Mesa's Measure "X" Zone that meet the requirements for operation can conduct wholesale medical marijuana distributing, manufacturing, processing and transporting as well as establish research and development and testing laboratories. Pivot intends to use this building to create a state-of-the-art GMP manufacturing facility to begin production of its suite of patented products to be marketed under the brand name 'Pivot Naturals'.
The development program will be led by Pivot's Executive Director of Formulations, Dr. Leonid Lurya , at the Company's contract lab in Israel . Pivot aims to bring finished additives to market that will include bulk cannabis powder for infusion into beverages by multi-national beverage companies and craft brewers interested in entering the massive cannabis market. As well, Pivot is currently developing cannabis in a single-use powder formula sachet and a water-soluble liquid solution in a concentrated dropper bottle that consumers can add to their favourite beverage.
"Pivot's industry leading product pipeline and Intellectual Property portfolio continues to attract attention from several groups, particularly in the food and beverage, nutraceutical and pharmaceutical industries," said Dr. Patrick Frankham , CEO of Pivot Pharmaceuticals. Dr. Frankham continued, "As a business, we see a glaring demand for differentiated products and solutions, backed by proven technologies, that match the vast needs of medicinal and recreational consumers outside of the dried flower segment. Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies.
Pivot Pharmaceuticals Makes Strategic Entry Into California Cannabis Market, Announces Listing on Frankfurt Stock Exchange
Mr. Rolfes continues to surround himself with proven, well-respected and experienced leaders in the scientific, legal, financial, and marketing and branding fields. As Pivot prepares for product launch in California in 2018, a consumer-facing brand is being developed for the entire company and will be unveiled in the coming weeks.
Dr. Wolfgang Renz Appointed Pivot's Chief Medical Officer Vancouver, British Columbia--(Newsfile Corp. - March 12, 2018) - Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) ("Pivot" or the "Company"), is pleased to announce that the Company has retained Cannabis Compliance Inc. ("CCI") to submit an application to Health Canada for a Dealer's License ("Dealer's License" or "DL") under the Controlled Drugs and Substances Act ("CDSA") and the Narcotic Control Regulations enacted thereunder on behalf ...